Ho Yi Chan, Stefanie;
Sheikh, Khalid;
Zariwala, Mohammed Gulrez;
Somavarapu, Satyanarayana;
(2023)
Dry powder formulation of azithromycin for COVID-19 therapeutics.
Journal of Microencapsulation
, 40
(4)
pp. 217-232.
10.1080/02652048.2023.2175924.
Preview |
Text
Somavarapu_Dry powder formulation of azithromycin for COVID 19 therapeutics (1).pdf Download (2MB) | Preview |
Abstract
Aim: The aim of this study is to develop dry powder formulations of azithromycin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocomposite microparticles for pulmonary delivery to improve the low bioavailability of azithromycin. Methods: Double emulsion method was used to produce nanoparticles, which were then spray dried to form nanocomposite microparticles. Encapsulation efficiency and drug loading were analysed, and formulations were characterised by particle size, zeta potential, morphology, crystallinity and in-vitro aerosol dispersion performance. Results: The addition of chitosan changed the neutrally-charged azithromycin only formulation to positively-charged nanoparticles. However, the addition of chitosan also increased the particle size of the formulations. It was observed in the NGI® data that there is an improvement in dispersibility of the chitosan-related formulations. Conclusion: It was demonstrated in this study that all dry powder formulations were able to deliver azithromycin to the deep lung regions, which suggests the potential of using azithromycin via pulmonary drug delivery as an effective method to treat COVID-19.
| Type: | Article |
|---|---|
| Title: | Dry powder formulation of azithromycin for COVID-19 therapeutics |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/02652048.2023.2175924 |
| Publisher version: | https://doi.org/10.1080/02652048.2023.2175924 |
| Language: | English |
| Additional information: | © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
| Keywords: | COVID-19, antibiotic, azithromycin, chitosan, dry powder formulations, dry powder inhaler, nanocomposite microparticles, nanoparticles, poly(lactic-co-glycolic acid) (PLGA), pulmonary drug delivery |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10165541 |
Archive Staff Only
 |
View Item |
